Pseudomonas aeruginosa: Properties, Virulence Factors, Lab Diagnosis, and Antibiotic Resistance

A 58-year-old man with severe burns covering 40% of his body surface area is admitted to the burns unit. By day 7, his wound swabs grow a Gram-negative rod producing blue-green pigmented colonies with a characteristic grape-like odor on blood agar. The isolate is oxidase-positive, non-lactose-fermenting on MacConkey, and grows at 42°C. Sensitivity testing reveals resistance to ampicillin, first-generation cephalosporins, trimethoprim, and co-trimoxazole. The wound smells distinctly of Pseudomonas.

Pseudomonas aeruginosa is the quintessential opportunistic pathogen: harmless to the healthy host, devastating to the compromised one. Burn patients, cystic fibrosis patients, ventilated ICU patients, and neutropenic cancer patients share one common threat: P. aeruginosa exploiting a disrupted host defense to establish infection that is notoriously difficult to treat.

In WHO's 2024 Bacterial Priority Pathogens List it is a High-priority pathogen for which new antibiotics are needed, downgraded from the Critical tier it held on the 2017 list as newer anti-pseudomonal agents reached the clinic.

Pseudomonas aeruginosa is a gram-negative rod. Pseudomonas aeruginosa can resist high concentrations of salt, dyes, weak antiseptics, and many commonly used antibiotics. Most pseudomonads known to cause disease in humans are associated with opportunistic infections.

Pseudomonas aeruginosa is by far the most clinically important species of the genus Pseudomonas. Stenotrophomonas maltophilia (formerly P. maltophilia) is a closely related GN non-fermenter that is sometimes discussed alongside Pseudomonas due to its similar resistance profile and nosocomial significance.

This opportunistic pathogen may infect virtually any tissue. Infection is facilitated by the presence of an underlying disease. It is a major threat to hospitalized patients, particularly those with serious underlying diseases such as cancer and burns (burning causes breakdown of nonspecific host defenses).

General Properties

Pseudomonas aeruginosa is:

• Gram-negative rod, 0.5–0.8 µm × 1.5–3.0 µm
• Motile by single polar flagellum (monotrichous)
• Obligate aerobe, strict aerobic respiratory metabolism (uses O₂ or NO₃⁻ as terminal electron acceptor)
• Non-spore-forming, non-capsulate (except mucoid strains which produce alginate)
• Oxidase-positive
• Non-fermenter of carbohydrates. It does not ferment glucose or lactose
• Grows at temperatures ranging from 4°C to 42°C; optimal 37°C; growth at 42°C distinguishes it from most other Pseudomonas species
• Distinctive grape-like or tortilla-like odor due to aminoacetophenone production, a useful bedside and laboratory clue
• Produces characteristic pyocyanin (blue-green), pyoverdine (yellow-green fluorescent), pyomelanin (brown-black), and pyorubin (red-brown) pigments
• Intrinsically resistant to many antibiotics (see Resistance section)

Sites of infection by P. aeruginosa

1. Central nervous system infections
2. Localized infections of the ear and sinus
3. Skin and musculoskeletal tissues, burn wounds, surgical wounds
4. Respiratory tract: chronic infections in cystic fibrosis patients, acute pneumonia in other patients
5. Bacteremia
6. Endocarditis
7. Urinary tract infections

Mortality in P. aeruginosa infection

Infections with P. aeruginosa are associated with a high mortality rate. This is because of the combination of

1. Bacterial resistance to antibiotics
2. Weakened host defenses
3. Production of extracellular bacterial enzymes and toxins.

Virulence Factors of Pseudomonas aeruginosa

P. aeruginosa produces an extensive arsenal of virulence determinants, more diverse than most bacterial pathogens, reflecting its capacity to infect virtually any host tissue.

1. Exotoxin A: The Primary Toxin

Exotoxin A is the most important virulence factor of P. aeruginosa and is produced by the majority of clinical isolates:

• Mechanism: identical to diphtheria toxin. ADP-ribosylation of elongation factor 2 (EF-2), blocking protein synthesis and causing cell death
• Target: Liver, heart, kidney, and lung cells; macrophages (inhibits phagocytosis)
• Clinical significance: Major contributor to tissue damage and organ failure in severe Pseudomonas infections; inhibits wound healing; associated with increased mortality

2. Type III Secretion System (T3SS)

The T3SS is a molecular syringe that injects effector proteins directly into host cells:

• ExoS and ExoT: GTPase-activating proteins and ADP-ribosyltransferases that disrupt the actin cytoskeleton, inhibiting phagocytosis and cell signaling
• ExoU: ExoU: phospholipase that rapidly destroys host cell membranes; highly cytotoxic; strongly associated with acute lung injury and poor prognosis in VAP
• ExoY: adenylate cyclase that increases intracellular cAMP; disrupts cell signaling
• Clinical significance: T3SS-positive strains are associated with more severe infection and higher mortality. ExoU-producing strains are particularly virulent.

3. Alginate (Biofilm): The Cystic Fibrosis Factor

Mucoid strains of P. aeruginosa produce alginate, a polysaccharide capsule that forms the matrix of biofilms:

• Protects bacteria from antibiotics (impairs diffusion) and host immune responses (inhibits phagocytosis, impairs complement activation)
• The defining feature of chronic P. aeruginosa infection in cystic fibrosis. Mucoid conversion is essentially irreversible and marks a turning point in disease progression
• Biofilm-embedded P. aeruginosa requires 100–1000× higher antibiotic concentrations than planktonic cells
• Source of the mucoid colony morphology seen on CF patient isolates

4. Pyocyanin

Pyocyanin (the blue-green phenazine pigment) is not merely a laboratory identification clue, it is an active virulence factor:

• Reactive oxygen species generation: Pyocyanin reacts with oxygen to produce superoxide and hydrogen peroxide, damaging host tissue
• Ciliostasis: Inhibits ciliary beat in respiratory epithelium, impairing mucociliary clearance
• Neutrophil killing: At high concentrations, toxic to neutrophils
• Antimicrobial activity: Inhibits competing bacteria, facilitating P. aeruginosa colonization

5. Proteases (Elastase and Alkaline Protease)

Two major extracellular proteases:

• Elastase (LasB): Degrades elastin (blood vessel walls, lung alveoli), collagen, IgG, IgA, complement components; responsible for hemorrhagic lesions and tissue necrosis
• Alkaline protease (AprA): Degrades collagen, fibrin, IgG, complement; contributes to tissue invasion

6. Flagella and Pili

• Flagella: Mediate motility (swarming); trigger TLR5-mediated host inflammatory response; facilitate initial attachment to mucus
• Type IV pili (TFP): Primary attachment factor to epithelial cells; mediate twitching motility; essential for biofilm formation

7. Lipopolysaccharide (LPS)

Like other Gram-negative organisms, LPS (O-antigen lipopolysaccharide) of P. aeruginosa:

• Triggers strong innate immune response via TLR4
• Non-mucoid strains: full-length LPS with O-antigen; mucoid (CF) strains often express rough LPS (no O-antigen), which helps evade antibody recognition

8. Hemolysins

Two types produced:

• Phospholipase C (glycolipid hemolysin): Degrades phospholipids in cell membranes; lyses RBCs and disrupts pulmonary surfactant, particularly important in CF lung disease
• Rhamnolipid: Biosurfactant that lyses red blood cells and inhibits phagocytosis; contributes to β-hemolysis on blood agar

Virulence Factor Summary

Laboratory Diagnosis

In the laboratory, P. aeruginosa can be isolated from any sample (urine, pus, blood, ear swabs, tissue biopsies, body fluids, etc.). They grow well on standard broth and solid media such as blood agar, chocolate agar, and MacConkey agar, which are recommended to isolate Pseudomonas species from clinical specimens. Selective agar-containing inhibitors such as cetrimide can also be used for isolation and presumptive identification.

Colony morphology

• On MacConkey agar colonies of P. aeruginosa are flat, 2-3 mm, smooth, non-lactose fermenting colonies with irregular margin (leafy margin) and slightly pigmented (greenish pigmentation).
• On Blood agar: It is documented that, P. aeruginosa isolates may produce three colony types on blood agar depending on the source of isolation.

Natural isolates from soil or water typically produce a small, rough colony. Clinical samples, yield one or another of two smooth colony types. On blood agar, Pseudomonas colonies are large with a metallic sheen, and may be mucoid, rough, or pigmented (pyocyanin), often with β-hemolysis

One type has a fried-egg appearance which is large, smooth, with flat edges and an elevated appearance. Another type, frequently obtained from respiratory and urinary tract secretions, has a mucoid appearance, which is attributed to the production of alginate slime.

• Cetrimide Agar is used as a selective medium for the isolation of Pseudomonas aeruginosa from pus, sputum and drains, etc. Pseudomonas aeruginosa produces yellow-green to blue colonies and fluoresces under UV light.

Gram stain

In a Gram-stained smear, Pseudomonas aeruginosa appears as a slender Gram-negative rod (0.5 to 0.8 µm by 1.5 to 3.0 µm), often arranged singly or in pairs, with no spores and no true capsule except in mucoid strains.

Biochemical characteristics

1. Pseudomonas aeruginosa is often preliminarily identified by its typical odor in vitro. The smell is described as grape-like, tortilla-like, or “Philadelphus coronarius-like” (production of aminoacetophenone).
2. Catalase-positive
3. Rapid oxidase-positive within 10 seconds (exception P. luteola and P. oryzihabitans)
4. Motile by means of one or more polar flagella.
5. It is a non-fermenter: it may oxidize glucose (producing acid oxidatively, not by fermentation) but does not ferment it, and is lactose-negative. Alkaline slant/alkaline deep (K/K) reaction in TSI or KIA agar.
6. Some strains of P. aeruginosa secrete a variety of pigments, including pyocyanin (blue-green), pyoverdine (yellow-green and fluorescent), pyomelanin (brown to black), and pyorubin (red-brown).
7. Strict aerobic respiratory metabolism with oxygen but in some cases, nitrate has been used as an alternative that allows anaerobic growth.
8. Can grow in temperatures up to 42°C. The combination of pyocyanin production and the ability to grow at 42°C is sufficient to distinguish P. aeruginosa from other Pseudomonas spp. (e.g., P. fluorescens, P. putida, P. stutzeri, P. putrefaciens).

All strains of P. aeruginosa may not produce Pyocyanin.

TSI result: Alkaline slant / Alkaline deep (K/K), no acid, no gas, no H₂S. This K/K pattern on TSI is characteristic of non-fermenters including Pseudomonas, Acinetobacter, and other GN non-fermenters. It directly distinguishes them from the Enterobacteriaceae which produce acid in the slant or butt.

Distinguishing Characteristics from Other Species

Note: All of these Pseudomonas species are lysine decarboxylase negative, Aesculin hydrolysis negative and Lactose utilization negative. Only Pseudomonas aeruginosa among these produces pyocyanin, and its growth at 42°C separates it from P. fluorescens and P. putida.

Several organisms once classified as Pseudomonas have been moved to other genera and are no longer listed above. The two you are most likely to meet as P. aeruginosa look-alikes on the bench are Stenotrophomonas maltophilia (formerly P. maltophila) and Burkholderia cepacia (formerly P. cepacia), both important nosocomial and cystic fibrosis non-fermenters. Burkholderia pseudomallei (melioidosis) and B. mallei (glanders), also former pseudomonads, are Tier 1 select agents handled under heightened biosafety.

Antibiotic Resistance: Why P. aeruginosa is a WHO High-Priority Pathogen

In its 2024 Bacterial Priority Pathogens List, WHO classifies carbapenem-resistant P. aeruginosa as a High-priority pathogen for the development of new antibiotics. This is a change from the 2017 list, where it sat in the Critical (Priority 1) tier.

The downgrade to High does not mean the organism became easier to treat. It reflects that several new anti-pseudomonal agents (for example ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam) have reached the clinic since 2017, easing the pipeline gap that drove the original Critical ranking.

The underlying problem, the convergence of intrinsic and acquired resistance mechanisms described below, is unchanged, and carbapenem-resistant P. aeruginosa remains one of the highest-burden hospital pathogens worldwide, especially in low- and middle-income settings.

Intrinsic Resistance (Present in All Strains)

Key implication: Every P. aeruginosa isolate is inherently resistant to ampicillin, first-generation cephalosporins, trimethoprim, co-trimoxazole, and most older β-lactams. These drugs are not relied on for Pseudomonas infections regardless of how the susceptibility test appears, because the intrinsic resistance can mask as apparent susceptibility in vitro.

Acquired Resistance (Variable, Clinical Problem)

Antibiotics Active Against P. aeruginosa (Anti-Pseudomonal Agents)

The following is exam-oriented background on which drug classes retain anti-pseudomonal activity and why, not treatment guidance; actual therapy is always guided by local susceptibility data and clinical protocols.

Combination therapy: For serious P. aeruginosa infections (bacteremia, pneumonia, endocarditis), combination therapy with two anti-pseudomonal agents from different classes is often used, not to achieve synergy (evidence is limited) but to reduce the risk of resistance emergence during treatment. Once susceptibility results are available, de-escalation to monotherapy is common practice.

Colistin as last resort: The revival of colistin for carbapenem-resistant P. aeruginosa (CRPA) reflects how severely resistance has limited treatment options. Colistin carries significant nephrotoxicity, which is why its use is tied closely to MIC testing.

Key Clinical Syndromes

Cystic Fibrosis (CF) Lung Infection

The most clinically significant P. aeruginosa infection by disease burden. Key features:

• Early colonization with non-mucoid strains; eventual mucoid conversion as alginate production is upregulated
• Mucoid conversion marks the transition from early (potentially treatable) to established chronic infection, and is essentially irreversible
• Repeated antibiotic courses select for progressively resistant strains; eventual pan-resistance is common
• Chronic lung inflammation driven by immune response to Pseudomonas (not direct tissue invasion) causes progressive lung function decline
• Inhaled antibiotics (tobramycin, aztreonam, colistin) are used to suppress rather than eradicate infection in CF

Burn Wound Infections

• Burns destroy the skin barrier, the primary physical defense against P. aeruginosa
• Hospital environment contamination (water sources, sink drains, respiratory equipment) provides the inoculum
• Blue-green pus and blue-green discoloration of wound dressings from pyocyanin is characteristic
• Bacteremia from burn wound sepsis carries very high mortality

Ventilator-Associated Pneumonia (VAP)

• Leading cause of VAP, particularly late-onset (>5 days of ventilation)
• Endotracheal tube biofilm provides a reservoir
• ExoU-producing strains associated with acute lung injury and rapid deterioration
• Diagnosis requires quantitative culture from BAL or protected specimen brush

Malignant (Necrotizing) Otitis Externa

• P. aeruginosa osteomyelitis of the temporal bone, typically in elderly diabetics
• Begins as persistent external ear infection spreading to skull base
• Characteristic: granulation tissue at junction of bony and cartilaginous ear canal
• Requires prolonged anti-pseudomonal therapy (often 4–8 weeks IV)

Ecthyma Gangrenosum

• Pathognomonic skin lesion of P. aeruginosa bacteremia in neutropenic patients
• Begins as an erythematous macule, progresses to a hemorrhagic bulla, then a necrotic black eschar
• Caused by vascular invasion and LPS/elastase-mediated tissue destruction
• Represents a dermatological emergency that indicates life-threatening bacteremia

How to Remember

The four characteristics that identify P. aeruginosa at the bench:

Grape + Green + Grows at 42 + Oxidase positive

1. Grape-like odor (aminoacetophenone)
2. Green-blue pigment (pyocyanin): not all strains produce it but highly specific when present
3. Growth at 42°C: distinguishes P. aeruginosa from P. fluorescens and P. putida
4. Oxidase positive within 10 seconds: distinguishes from Enterobacteriaceae

The non-fermenter rule: TSI = K/K (alkaline/alkaline, no acid, no gas, no H₂S) = non-fermenter Pseudomonas, Acinetobacter, Stenotrophomonas all show K/K on TSI Contrast with Enterobacteriaceae: K/A (glucose fermented, no lactose) or A/A (both fermented)

The resistance memory anchor, three layers:

1. Intrinsic: AmpC + low permeability + MexAB pump → resistant to ampicillin, TMP, early cephalosporins by default
2. Inducible: AmpC can be de-repressed → apparent susceptibility to piperacillin/ceftazidime during treatment converts to resistance
3. Acquired: OprD loss → carbapenem resistance; MBL acquisition → resistance to almost everything

The CF progression story: Non-mucoid → mucoid conversion (alginate production) → biofilm establishment → treatment suppression, not cure → progressive resistance

Ecthyma gangrenosum as the clinical anchor: Black necrotic skin lesion in a neutropenic, febrile patient = Pseudomonas bacteremia until proven otherwise. Mechanism: vascular invasion → thrombosis → ischemic necrosis

Key exam facts in one table

References

1. Public Health England. (2015). Identification of Pseudomonas species and other Non-Glucose Fermenters. UK Standards for Microbiology Investigations. ID 17 Issue 3.
2. Tille PM. Bailey and Scott's Diagnostic Microbiology. 15th ed. St. Louis: Elsevier; 2022.
3. Diggle, S.P., & Whiteley, M. (2020). Microbe Profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat. Microbiology, 166(1), 30–33. https://doi.org/10.1099/mic.0.000860
4. Gellatly, S. L., & Hancock, R. E. (2013). Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathogens and Disease, 67(3), 159–173. https://doi.org/10.1111/2049-632X.12033
5. World Health Organization. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Geneva: WHO; 2024.